The estimated Net Worth of Alexander Edward Iii Kuta is at least 2.75 百万$ dollars as of 7 March 2023. Alexander Kuta owns over 585 units of uniQure N.V stock worth over 494,384$ and over the last 7 years he sold QURE stock worth over 902,572$. In addition, he makes 1,353,030$ as Executive Vice President、 Operations at uniQure N.V.
Alexander has made over 29 trades of the uniQure N.V stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 585 units of QURE stock worth 12,496$ on 7 March 2023.
The largest trade he's ever made was exercising 37,762 units of uniQure N.V stock on 27 July 2022 worth over 200,516$. On average, Alexander trades about 4,595 units every 41 days since 2018. As of 7 March 2023 he still owns at least 90,381 units of uniQure N.V stock.
You can see the complete history of Alexander Kuta stock trades at the bottom of the page.
Dr. Alexander Edward Kuta Ph.D., III serves as Executive Vice President, Operations of the Company. Prior to joining uniQure, he was Vice President of Research & Development Global Regulatory Affairs for EMD Serono, responsible for immune-mediated diseases, oncology and biologics regulatory CMC, from January 2016 to September 2016. He joined EMD Serono in April 2013 as Vice President, Head of US Regulatory Affairs; while at EMD Serono he served on the US Leadership Team. From April 2012 to March 2013, Dr. Kuta was Vice President of Global Regulatory Affairs and a member of the Executive Leadership Team at Lantheus Medical Imaging. His previous industry experience includes senior regulatory leadership roles at AMAG Pharmaceuticals (NASDAQ: AMAG) from August 2010 to April 2012 as well as Genzyme Corporation from August 1995 to July 2010 where he worked in the areas of rare diseases, cell and gene therapy, therapeutic proteins and biomaterials. Prior to joining industry, he was Chief of the Cytokine and Gene Therapy Branch in the Center for Biologics at FDA from January 1993 to August 1995 and a Scientific Reviewer from January 1990 to January 1993. Dr. Kuta has served on the BIO Regulatory Affairs Leadership Committee - Cell and Gene Therapy Working Group, as reviewer for the National Gene Vector Laboratories program, on the ICH (M6) Gene Therapy Working Group and is currently on the scientific review board of the Gene Therapy Resource Program of NHLBI/NIH. Dr. Kuta holds a Bachelor of Science degree from Saint John’s University, Collegeville, MN and a Ph.D. from the Chicago Medical School at Rosalind Franklin U-Med & Science. He conducted his post-doctoral studies at the National Cancer Institute/National Institutes of Health.
As the Executive Vice President、 Operations of uniQure N.V, the total compensation of Alexander Kuta at uniQure N.V is 1,353,030$. There are 2 executives at uniQure N.V getting paid more, with Matthew Kapusta having the highest compensation of 4,719,960$.
Alexander Kuta is 60, he's been the Executive Vice President、 Operations of uniQure N.V since . There are 4 older and 11 younger executives at uniQure N.V. The oldest executive at uniQure N.V. is Jack Kaye, 76, who is the Non-Executive Independent Director.
Alexander's mailing address filed with the SEC is C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.
Over the last 8 years, insiders at uniQure N.V have traded over 35,572,573$ worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van、Paula Soteropoulos、William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of 37,634$. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth 6,309$.
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
uniQure N.V executives and other stock owners filed with the SEC include: